Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	120.77	128.94	8.57	63.57	20.34
Revenue Growth (YoY)	-6.33%	1404.02%	-86.52%	212.55%	-
Cost of Revenue	21.21	21.01	8.89	-	-
Gross Profit	99.56	107.93	-0.31	-	-
Selling, General & Admin	26.25	39.89	50.91	71.55	78.8
Research & Development	37.45	151.48	224.79	272.53	282
Total Operating Expenses	63.7	191.37	275.69	344.09	360.8
Operating Income	35.86	-83.44	-276.01	-280.51	-340.46
Interest Income	0.68	2.11	5.43	3.06	-
Interest Expense	-3.79	-4.62	-5.29	-0.37	-
Other Non-Operating Income (Expense)	-0.03	0.53	-0.25	49.54	-
Total Non-Operating Income (Expense)	-3.14	-1.98	-0.11	52.22	0.73
Pretax Income	32.72	-85.42	-276.11	-228.29	-340.1
Provision for Income Taxes	0.03	-0.01	0.02	0.01	0.05
Net Income	32.69	-85.4	-276.13	-228.3	-340.14
Net Income to Common	32.69	-85.4	-276.13	-228.3	-340.14
Shares Outstanding (Basic)	13	7	4	4	4
Shares Outstanding (Diluted)	13	7	4	4	4
Shares Change (YoY)	69.84%	76.77%	3.83%	8.88%	26.63%
EPS (Basic)	2.61	-11.41	-65.19	-56.00	-90.75
EPS (Diluted)	2.57	-11.41	-65.19	-56.00	-90.75
Shares Outstanding	7.32	5.86	4.26	3.84	3.67
Free Cash Flow	-50.94	-68.96	-194.2	-274.62	-231.1
Free Cash Flow Per Share	-4.01	-9.21	-45.85	-67.32	-61.68
Gross Margin	82.44%	83.71%	-3.65%	100.00%	100.00%
Operating Margin	29.69%	-64.71%	-3219.48%	-441.25%	-1673.85%
Profit Margin	27.07%	-66.23%	-3220.88%	-359.12%	-1672.28%
FCF Margin	-42.18%	-53.48%	-2265.25%	-431.98%	-1136.19%
EBITDA	37.98	-78.39	-271.18	-274.86	-331.12
EBITDA Margin	31.45%	-60.79%	-3163.15%	-432.35%	-1627.91%
EBIT	35.86	-83.44	-276.01	-280.51	-340.46
EBIT Margin	29.69%	-64.71%	-3219.48%	-441.25%	-1673.85%
Effective Tax Rate	0.09%	0.01%	-0.01%	-0.01%	-0.01%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q